Research Library
APEX — PerfusionInositol-Stabilized Arginine Silicate

NooLVL®

1,500 mg of inositol-stabilized arginine silicate — the patented nitric oxide precursor clinically shown to improve reaction time, cognitive flexibility, and sustained attention through a nitric oxide pathway that supports cerebral blood flow, independent of caffeine’s mechanism.

8 min read 4 Clinical Trials 1,500 mg per serving

Primacy Research

Key Benefits

What NooLVL® Does For You

Enhanced Cerebral Blood Flow

NooLVL® delivers stabilized arginine for nitric oxide production, driving NO/cGMP-mediated vasodilation in cerebral vasculature — increasing oxygen and glucose delivery to neurons under cognitive load.

Faster Reaction Time & Accuracy

Tartar et al. (2019) demonstrated improved reaction time, accuracy, and visual processing at exactly 1,500 mg — the same dose delivered in every APEX serving.

Improved Executive Function

Kalman et al. (2016) showed significant improvement on Trail Making Test-B (28–35% improvement) — a validated measure of cognitive flexibility, processing speed, and executive function.

Caffeine Counterbalance

NooLVL® dilates cerebral vessels through the NO/cGMP pathway, independent of adenosine signaling — designed to counterbalance caffeine’s 20–30% cerebrovascular constriction while preserving its alertness benefits.

Full Clinical Dose — Zero Compromise

Every published NooLVL® clinical trial used exactly 1,500 mg. APEX delivers the full patented dose developed and validated by Nutrition21 — no underdosing.

Watch the deep dive overview
The Problem

Your Brain Is Underperfused Under Load

The brain consumes 20% of cardiac output despite being 2% of body mass. During demanding cognitive tasks, regional metabolic demand spikes 30–50% — and if cerebral blood flow can’t match, performance degrades. Worse, the 152 mg caffeine in APEX constricts cerebral vessels by 20–30% through adenosine blockade. You need a counterbalance that delivers blood flow through a completely independent pathway.

Neurovascular Mismatch

When neural activity increases, blood flow must follow (neurovascular coupling). Age-related endothelial dysfunction impairs this coupling — active brain regions don’t receive the oxygen and glucose they demand, causing processing slowdowns, mental fatigue, and attention lapses.

Caffeine’s Hidden Cost

Caffeine blocks adenosine receptors that normally promote vasodilation. The cognitive benefits come from neural excitability, but the vascular cost is a 20–30% reduction in cerebral blood flow. Without a counterbalance, you trade blood flow for alertness.

The Arginine Paradox

L-arginine is the substrate for nitric oxide, but oral L-arginine has poor bioavailability — arginase in the gut and liver degrades it before it reaches systemic circulation. Only ~1–2% of oral L-arginine contributes to NO production. Standard arginine supplementation often fails to raise NO meaningfully.

Mechanism of Action

How NooLVL® Works

NooLVL® is a patented inositol-stabilized arginine silicate complex developed by Nutrition21. The inositol stabilization solves the fundamental bioavailability problem that makes free L-arginine supplementation ineffective for nitric oxide production.

01

Stabilized Arginine Release

NooLVL® is a bonded complex of arginine, silicon (silicate), and inositol. The inositol coating prevents arginase degradation in the gut and liver — the bottleneck that makes free L-arginine supplementation ineffective. This delivers significantly more arginine to the systemic circulation for NO synthesis.

02

eNOS/nNOS → Nitric Oxide

Released arginine serves as the direct substrate for nitric oxide synthase: L-arginine + O₂ → L-citrulline + NO. In endothelium, eNOS produces NO for vasodilation. In neurons, nNOS produces NO as a retrograde neurotransmitter that modulates synaptic plasticity and neurovascular coupling.

03

NO → cGMP → Vasodilation

Nitric oxide diffuses into vascular smooth muscle, activating soluble guanylate cyclase (sGC). sGC increases cGMP, which activates protein kinase G (PKG) — causing smooth muscle relaxation and vasodilation. In cerebral vasculature, this increases blood flow to active brain regions.

04

Cerebral Perfusion Enhancement

Increased NO-mediated vasodilation is thought to deliver more oxygen and glucose to neurons under cognitive load. This may counterbalance caffeine’s vasoconstrictive effect through an independent pathway (NO/cGMP vs. adenosine receptors), preserving the alertness benefit while supporting blood flow through an independent route.

Clinical Evidence

What the Research Shows

NooLVL® is backed by multiple randomized, double-blind, placebo-controlled trials — all using the exact 1,500 mg dose delivered in APEX.

2019 RCTDouble-blind, placebo-controlled · n=60 healthy adults
1500 mg
Exact APEX Dose Validated
Improved reaction time + accuracy in competitive gamers
7 days
Duration to Full Cognitive Effect
Acute + sustained benefits (Tartar et al.)
Cognitive Performance — NooLVL vs. Placebo
Reaction Time
Sig. ↑
Accuracy
Sig. ↑
Short-Term Memory
Sig. ↑
Placebo
Baseline

Tartar, J. L., Kalman, D., & Hewlings, S. (2019). A prospective study evaluating the effects of a nutritional supplement intervention on cognition, mood states, and mental performance in video gamers. Nutrients, 11(10), 2326.

2021 RCTDouble-blind, placebo-controlled · n=19 healthy adults
19
Healthy Adults Tested
Improved short-term memory + task-switching + reduced mental fatigue

Gills, J. L., et al. (2021). Acute inositol-stabilized arginine silicate improves cognitive outcomes in healthy adults. Nutrients, 13(12), 4272.

2016 RCTDouble-blind, placebo-controlled, crossover · n=24
24
Healthy Adults Tested
Improved Trail Making Test B (executive function) + elevated NO levels

Kalman et al. (2016). Nutrients. 1,500 mg ASI for 14 days. Improved cognitive flexibility and salivary NO metabolites.

Dosage & Bioavailability

Your Daily Dose in APEX

Clinical Dose
1,500 mg
Per day — exact dose across ALL published NooLVL RCTs
APEX Delivers
1,500 mg
NooLVL® per serving — full clinical dose, zero compromise
vs. L-Arginine
Superior
More bioavailable arginine for NO production (bypasses arginase)

Why this dose works: Every published NooLVL clinical trial used exactly 1,500 mg — there is no ambiguity about dose validation. This is the patented dose developed and studied by Nutrition21. APEX delivers the full clinical amount with zero compromise.

Formula Synergy

How NooLVL® Connects Across the System

NooLVL® doesn’t work in isolation. Inside the Primacy protocol, it anchors a triple nitric oxide architecture and counterbalances caffeine’s cerebrovascular cost — while feeding oxygen into the mitochondrial energy pipeline.

APEX

Triple Nitric Oxide Architecture

NooLVL® is designed to provide the arginine substrate for NO synthase. CocoaNol® is positioned to activate eNOS and protect NO from oxidative degradation via high-flavanol cocoa polyphenols. Cereboost® is intended to upregulate eNOS expression through ginsenoside-mediated PI3K/Akt signaling. Three independent inputs — substrate, enzyme activation, enzyme upregulation — into one NO/vasodilation output.

APEX

The Caffeine Counterbalance

Caffeine constricts cerebral vessels via adenosine receptor blockade — a 20–30% reduction in cerebral blood flow. NooLVL® is designed to dilate via the NO/cGMP pathway, which is independent of adenosine signaling. The intended result: caffeine’s alertness and focus benefits are preserved while blood flow is supported through a separate mechanism. Two opposing forces, two independent pathways, one optimized design.

APEX → RESET

Perfusion → Mitochondrial Pipeline

NooLVL® is designed to increase oxygen delivery to neurons under cognitive load. BioPQQ® is intended to stimulate new mitochondrial biogenesis. ALCAR shuttles fatty acids into those mitochondria for fuel. Overnight, RESET continues the cycle: Pycnogenol® is positioned to maintain endothelial blood flow for repair, while CoQ10 replenishes the cellular energy reserves that daytime perfusion supports.

Summary

Key Takeaways

01

Full Clinical Dose, Every Study

All 4 published NooLVL RCTs used exactly 1,500 mg. APEX delivers exactly that — the patented dose developed and validated by Nutrition21 with zero compromise.

02

The Caffeine Counterbalance

NooLVL® is designed to support cerebral blood flow through the NO/cGMP pathway while caffeine drives alertness via adenosine blockade. Two independent mechanisms, one optimized design — alertness without the blood flow penalty.

03

Triple NO Architecture

NooLVL® (substrate) + CocoaNol® (enzyme activation) + Cereboost® (enzyme upregulation) are designed to provide three independent inputs into nitric oxide production — a multi-pathway system intended to support cerebral perfusion.

04

Beyond L-Arginine

Inositol stabilization bypasses arginase degradation in the gut and liver, delivering substantially more bioavailable arginine for NO production than free L-arginine. Standard arginine supplements often fail; NooLVL® was engineered to solve that problem.

FAQ

Frequently Asked Questions

What is NooLVL®?

NooLVL® is a patented inositol-stabilized arginine silicate complex developed by Nutrition21. It is designed to deliver bioavailable arginine for nitric oxide production, bypassing the arginase degradation that makes standard L-arginine supplementation ineffective.

How is NooLVL® different from L-arginine?

Oral L-arginine is extensively degraded by arginase in the gut and liver — only ~1–2% contributes to NO production. NooLVL®’s inositol stabilization prevents this degradation, delivering substantially more bioavailable arginine to the systemic circulation for nitric oxide synthesis.

What cognitive benefits has NooLVL® shown in clinical trials?

Multiple RCTs at exactly 1,500 mg have demonstrated improved reaction time, accuracy, short-term memory, cognitive flexibility (Trail Making Test-B), and reduced mental fatigue — with some effects observed acutely and others over sustained supplementation periods.

Why does APEX need a blood flow ingredient alongside caffeine?

Caffeine blocks adenosine receptors for alertness, but this also constricts cerebral blood vessels by 20–30%. NooLVL® dilates through the independent NO/cGMP pathway, designed to preserve caffeine’s cognitive benefits while supporting cerebral blood flow through a separate mechanism.

What is the Triple NO Architecture in APEX?

APEX combines three independent inputs into nitric oxide production: NooLVL® (arginine substrate), CocoaNol® (eNOS enzyme activation via epicatechin), and Cereboost® (eNOS upregulation via ginsenoside PI3K/Akt signaling). Substrate + enzyme activation + enzyme upregulation.

How much NooLVL® is in APEX?

APEX delivers exactly 1,500 mg of NooLVL® per serving — the full clinical dose used in every published RCT. This is the patented dose developed and validated by Nutrition21 with zero compromise.

References

References

  1. [1]
    Tartar, J. L., Kalman, D., & Hewlings, S. (2019). A prospective study evaluating the effects of a nutritional supplement intervention on cognition, mood states, and mental performance in video gamers. Nutrients, 11(10), 2326.View
  2. [2]
    Sowinski, R., et al. (2021). Effects of inositol-enhanced bonded arginine silicate ingestion on cognitive and executive function in gamers. Nutrients, 13(11), 3758.View
  3. [3]
    Gills, J. L., et al. (2021). Acute inositol-stabilized arginine silicate improves cognitive outcomes in healthy adults. Nutrients, 13(12), 4272.View
  4. [4]
    Kalman, D., Harvey, P. D., Perez Ojalvo, S., & Komorowski, J. (2016). Randomized prospective double-blind studies to evaluate the cognitive effects of inositol-stabilized arginine silicate in healthy physically active adults. Nutrients, 8(11), 736.View

Upgrade Your Cerebrovascular Performance

NooLVL® is one of 28 active ingredients in APEX, engineered to work as a system — not a stack of standalone compounds.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.